Huber Capital Management LLC Invests $1.23 Million in Icon Plc $ICLR

Huber Capital Management LLC bought a new position in shares of Icon Plc (NASDAQ:ICLR) during the 4th quarter, HoldingsChannel reports. The fund bought 6,760 shares of the medical research company’s stock, valued at approximately $1,232,000.

Other institutional investors have also recently made changes to their positions in the company. Toth Financial Advisory Corp purchased a new stake in shares of Icon during the 4th quarter valued at approximately $27,000. Ameriflex Group Inc. purchased a new stake in Icon in the third quarter valued at approximately $33,000. Johnson Financial Group Inc. purchased a new stake in Icon in the third quarter valued at approximately $71,000. Quadrant Capital Group LLC purchased a new stake in Icon in the third quarter valued at approximately $78,000. Finally, Geneos Wealth Management Inc. raised its position in Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analysts Set New Price Targets

ICLR has been the topic of a number of research analyst reports. Bank of America reissued an “outperform” rating on shares of Icon in a research report on Monday, June 1st. BMO Capital Markets boosted their target price on Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research report on Friday, May 29th. JPMorgan Chase & Co. boosted their target price on Icon from $120.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, May 29th. Leerink Partners set a $145.00 target price on Icon in a research report on Thursday, May 28th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $165.00 target price on shares of Icon in a research report on Friday, May 29th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Icon presently has an average rating of “Hold” and a consensus target price of $156.44.

Icon Stock Performance

NASDAQ:ICLR opened at $146.18 on Friday. The company has a fifty day simple moving average of $121.76 and a two-hundred day simple moving average of $140.47. The company has a market cap of $11.19 billion, a price-to-earnings ratio of 23.73, a price-to-earnings-growth ratio of 11.55 and a beta of 1.26. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, June 17th. The medical research company reported $2.52 EPS for the quarter, topping the consensus estimate of $2.47 by $0.05. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $1.99 billion. Icon had a net margin of 5.98% and a return on equity of 9.50%. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.43 earnings per share. As a group, equities analysts anticipate that Icon Plc will post 9.74 earnings per share for the current fiscal year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.